USA - NASDAQ:EDAP - US2683111072 - ADR
The current stock price of EDAP is 2.08 USD. In the past month the price decreased by -12.45%. In the past year, price decreased by -15.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.92 | 225.09B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.07 | 194.65B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.06 | 148.87B | ||
| SYK | STRYKER CORP | 27.32 | 137.54B | ||
| BDX | BECTON DICKINSON AND CO | 13.3 | 54.98B | ||
| IDXX | IDEXX LABORATORIES INC | 53.35 | 53.82B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.79 | 49.47B | ||
| RMD | RESMED INC | 24.84 | 35.89B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.41 | 32.30B | ||
| PODD | INSULET CORP | 72.67 | 23.38B | ||
| DXCM | DEXCOM INC | 32.02 | 23.35B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.06 | 17.73B |
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 310 full-time employees. The firm's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. The company specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. The company also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
EDAP TMS SA -ADR
4, rue du Dauphine, PA La Poudrette Lamartine
Vaulx-en-Velin AUVERGNE-RHONE-ALPES 69120 FR
CEO: Marc Oczachowski
Employees: 310
Phone: 33472153150
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 310 full-time employees. The firm's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. The company specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. The company also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
The current stock price of EDAP is 2.08 USD.
EDAP does not pay a dividend.
EDAP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
EDAP TMS SA -ADR (EDAP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.6).
EDAP TMS SA -ADR (EDAP) currently has 310 employees.
ChartMill assigns a technical rating of 3 / 10 to EDAP. When comparing the yearly performance of all stocks, EDAP is one of the better performing stocks in the market, outperforming 86.01% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to EDAP. Both the profitability and financial health of EDAP have multiple concerns.
Over the last trailing twelve months EDAP reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS increased by 11.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.75% | ||
| ROE | -75.53% | ||
| Debt/Equity | 0.26 |
9 analysts have analysed EDAP and the average price target is 5.88 USD. This implies a price increase of 182.79% is expected in the next year compared to the current price of 2.08.
For the next year, analysts expect an EPS growth of -41.53% and a revenue growth -6.7% for EDAP